rs77375493
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
|
|
|
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Identification of the Val617Phe JAK2 mutation lays the foundation for new approaches to the diagnosis, classification, and treatment of myeloproliferative disorders.
|
15781101 |
2005 |
rs77375493
|
|
T |
0.800 |
GeneticVariation |
CLINVAR |
Identification of the Val617Phe JAK2 mutation lays the foundation for new approaches to the diagnosis, classification, and treatment of myeloproliferative disorders.
|
15781101 |
2005 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.
|
15860661 |
2005 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The recently described V617F mutation in the Janus kinase 2 (JAK2) gene allows defining subclasses of patients with myeloproliferative disorders based on the JAK2 genotype.
|
16081684 |
2005 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
An association between an activating JAK2 mutation (JAK2(V617F)) and BCR/ABL-negative myeloproliferative disorders was recently reported in multiple simultaneous publications.
|
16225651 |
2005 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The V617F JAK2 mutation and the myeloproliferative disorders.
|
16285006 |
2006 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The nature of the specific oncogenic mutation(s) is currently being unraveled with the recent discovery of an association between a somatic point mutation of JAK2 tyrosine kinase (V617F) and bcr/abl-negative myeloproliferative disorders, including MMM.
|
16293880 |
2005 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Although the V617F JAK2 mutation has been described by several groups to be associated with classical myeloproliferative disorders (MPD), this same mutation has been detected with a low incidence in atypical MPD, such as CNL.
|
16330446 |
2005 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.
|
16373657 |
2006 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
|
16408098 |
2006 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders.
|
16537803 |
2006 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.
|
16572198 |
2006 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
DNA from 161 samples was isolated from peripheral blood granulocytes and formalin-fixed bone marrow clot sections in patients with CMPDs and without myeloproliferative disorders previously genotyped for the JAK2 V617F (G-->T) mutation, which included 114 wild types (GG) and 47 mutants (GT and TT).
|
16627272 |
2006 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The V617F activating point mutation in Jak2 has recently been associated with myeloproliferative disorders.
|
16632470 |
2006 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Questions remain regarding the exact contribution of JAK2(V617F) in other myeloproliferative disorders.
|
16670266 |
2006 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Recent information regarding disease pathogenesis, including a contribution to the myeloproliferative disorder phenotype by a gain-of-function JAK2 mutation (JAK2(V617F)), has revived the prospect of targeted therapeutics as well as molecular monitoring of treatment response.
|
16675707 |
2006 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.
|
16675710 |
2006 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In addition, Bcr/Abl-negative classic myeloproliferative disorders are characterized by recurrent JAK2(V617F) mutations, whereas other mutations affecting the RAS signaling pathway molecules have been associated with juvenile myelomonocytic leukemia.
|
16781478 |
2006 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients.
|
16810610 |
2006 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The main conclusion is that JAK2 V617F is a 100% specific clue to a new distinct clonal myeloproliferative disorder.
|
16810614 |
2006 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
JAK2(V617F) was identified in patients previously diagnosed with a myeloproliferative disorder or acute myeloid leukemia transformed from myeloproliferative disorder, whereas a wild-type genotype was identified in patients with reactive conditions or de novo acute myeloid leukemia.
|
16831057 |
2006 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The acquired mutation Val617Phe in the tyrosine kinase JAK2 was recently identified in most but not all patients with classical myeloproliferative disorders.
|
16885051 |
2006 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disorders.
|
16901656 |
2007 |
rs77375493
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We aimed to determine the relative sensitivity of four separate molecular assays used to detect the presence of the JAK2 V617F mutation in peripheral blood from patients with essential thrombocythaemia and related myeloproliferative disorders.
|
16916724 |
2006 |